Better Living Through Chemistry: Biopharma Investors Weigh In

In START UP’s third annual Life Science VC Survey, those who invest in biopharmaceuticals are feeling good about the IPO window and the helping hand from corporate VCs, and for the third year in a row, they say oncology and rare diseases are top investment targets. Their skepticism about asset-based financing has grown, however, even as new twists on the model emerge.

More from United States

More from North America